Covestor’s Atea Pharmaceuticals AVIR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$0 Buy
43
+7
+19% +$36 ﹤0.01% 2341
2026
Q2
$0 Buy
+36
New +$179 ﹤0.01% 2480
2025
Q4
– Sell
-93
Closed – – 2260
2025
Q3
$0 Buy
93
+8
+9% +$27 ﹤0.01% 2279
2025
Q2
$0 Buy
85
+3
+4% +$9 ﹤0.01% 2199
2025
Q1
$0 Buy
82
+15
+22% +$47 ﹤0.01% 2207
2024
Q4
$0 Buy
67
+1
+2% +$3 ﹤0.01% 2223
2024
Q3
$0 Sell
66
-52
-44% -$189 ﹤0.01% 2206
2024
Q2
$0 Buy
+118
New +$440 ﹤0.01% 2232
2023
Q3
– Sell
-83
Closed – – 2104
2023
Q2
$0 Sell
83
-929
-92% -$3.48K ﹤0.01% 2121
2023
Q1
$3K Buy
+1,012
New +$4.1K ﹤0.01% 1651
2022
Q1
– Sell
-40
Closed – – 2093
2021
Q4
$0 Buy
+40
New +$623 ﹤0.01% 2104

Other funds holding AVIR

Covestor's AVIR Position: Q3 2026 in Review

Covestor increased its Atea Pharmaceuticals (AVIR) stake by 19% in Q3 2026, buying an estimated $36 and bringing the position to 43 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2341.

Covestor first reported a position in AVIR in Q4 2021 and has held it in 11 quarters since. The position peaked at $3K in Q1 2023. 89 funds tracked by Wall St. Rank hold AVIR as of Q3 2026.

  • Covestor held 43 shares of Atea Pharmaceuticals worth $0 as of Q3 2026.
  • Covestor bought 7 Atea Pharmaceuticals shares in Q3 2026, an estimated $36.
  • Atea Pharmaceuticals made up ﹤0.01% of Covestor's portfolio in Q3 2026, its #2341 holding.
  • Covestor first reported a position in Atea Pharmaceuticals in Q4 2021 and has held it in 11 quarters since.
  • Covestor's Atea Pharmaceuticals position peaked at $3K in Q1 2023.
  • 89 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2026.

Based on Covestor's 13F filing for Q3 2026, filed 30 Oct 2026.